And then this part.:
VIII. CONCLUSION
Regarding GRR’s contract claims, we hold that the evidence is legally and factually sufficient to support the trial court’s implied findings that Shortt acted within the scope of his apparent authority in executing the Second Agreement. Because the Second Agreement contains a Texas forum-selection clause, the trial court did not err in concluding that Central expressly consented to specific jurisdiction over GRR’s contract claims. The allegations and evidence that Central negotiated and executed a contract in Texas containing a Texas forum-selection clause and a Texas choice-of-law provision support the conclusion that Central purposefully availed itself of the benefits and protections of Texas laws. We further conclude that the Second Agreement is not rendered unenforceable for jurisdictional purposes on the grounds that the original signed contract was lost, or that it does not specify the amount of GRR’s success fee, or that it allegedly was fabricated.
38
Regarding GRR’s tort claims of quantum meruit and fraudulent misrepresentation, we conclude that there is a substantial connection between Texas and the operative facts of the litigation. Finally, we hold that the trial court’s exercise of personal jurisdiction over GRR’s contract, quantum meruit, and fraudulent-misrepresentation claims against Central comports with traditional notions of fair play and substantial justice. Because the trial court did not err in exercising specific jurisdiction over each of these claims, we affirm the trial court’s denial of Central’s special appearance.
/s/ Tracy Christopher Justice
Panel consists of Justices Christopher, Brown, and Wise.
- Forums
- ASX - By Stock
- CTP
- True to form
CTP
central petroleum limited
Add to My Watchlist
1.85%
!
5.5¢

True to form, page-37
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
5.5¢ |
Change
0.001(1.85%) |
Mkt cap ! $40.98M |
Open | High | Low | Value | Volume |
5.4¢ | 5.5¢ | 5.4¢ | $91.62K | 1.696M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 449381 | 5.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.8¢ | 6030 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 449381 | 0.054 |
1 | 100000 | 0.053 |
3 | 719000 | 0.052 |
1 | 800000 | 0.051 |
2 | 39000 | 0.050 |
Price($) | Vol. | No. |
---|---|---|
0.058 | 6030 | 1 |
0.059 | 379120 | 4 |
0.060 | 160000 | 3 |
0.061 | 100000 | 1 |
0.067 | 149268 | 1 |
Last trade - 15.59pm 27/06/2025 (20 minute delay) ? |
Featured News
CTP (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online